Arcellx, Inc. (NASDAQ:ACLX – Get Free Report) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 4,470,000 shares, a decline of 10.6% from the July 15th total of 5,000,000 shares. Based on an average daily volume of 481,100 shares, the days-to-cover ratio is presently 9.3 days. Currently, 11.1% of the company’s shares are sold short.
Wall Street Analysts Forecast Growth
ACLX has been the subject of a number of research analyst reports. Canaccord Genuity Group restated a “buy” rating and issued a $85.00 target price on shares of Arcellx in a research note on Monday, July 22nd. Stifel Nicolaus raised their price objective on Arcellx from $82.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, May 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $81.00 target price on shares of Arcellx in a report on Friday, August 9th. Truist Financial reiterated a “buy” rating and issued a $87.00 price target on shares of Arcellx in a report on Tuesday, June 18th. Finally, HC Wainwright decreased their price objective on shares of Arcellx from $82.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Thirteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $78.00.
Read Our Latest Stock Analysis on Arcellx
Insider Activity
Institutional Investors Weigh In On Arcellx
A number of institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC purchased a new position in Arcellx in the 2nd quarter worth approximately $27,000. Plato Investment Management Ltd purchased a new position in Arcellx in the first quarter worth approximately $51,000. Decheng Capital LLC acquired a new stake in Arcellx during the second quarter worth $65,000. National Bank of Canada FI increased its stake in Arcellx by 50.0% during the second quarter. National Bank of Canada FI now owns 1,500 shares of the company’s stock worth $80,000 after acquiring an additional 500 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado purchased a new stake in Arcellx in the second quarter valued at $178,000. Institutional investors and hedge funds own 96.03% of the company’s stock.
Arcellx Stock Performance
Shares of NASDAQ ACLX opened at $65.28 on Monday. The company has a market capitalization of $3.49 billion, a PE ratio of -63.38 and a beta of 0.23. The company’s fifty day moving average price is $57.81 and its 200 day moving average price is $59.23. Arcellx has a 1 year low of $30.88 and a 1 year high of $75.10.
Arcellx (NASDAQ:ACLX – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.01. Arcellx had a negative net margin of 38.39% and a negative return on equity of 13.11%. The business had revenue of $27.38 million for the quarter, compared to analyst estimates of $22.04 million. The firm’s revenue was up 91.5% on a year-over-year basis. On average, equities analysts expect that Arcellx will post -1.7 EPS for the current year.
Arcellx Company Profile
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Recommended Stories
- Five stocks we like better than Arcellx
- Most active stocks: Dollar volume vs share volume
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What is a Bond Market Holiday? How to Invest and Trade
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.